Related Experiment Video
Updated: Jan 23, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
CD73: an emerging checkpoint for cancer immunotherapy
Siqi Chen1, Derek A Wainwright2, Jennifer D Wu3
1Robert H Lurie Comprehensive Cancer Center, Department of Medicine-Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Abstract:
CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis. The inhibition of CD73, in combination with immune checkpoint blockade, targeted therapy or conventional therapy, improves antitumor effects in numerous preclinical mouse models of cancer. Emerging evidence suggests that the combination of anti-CD73 and immune checkpoint blockade has promising clinical activity in patients with advanced solid tumors. In this review, we will discuss the specific role of CD73 on both tumor cells and nontumor cells in regulating tumor immunity and tumorigenesis and provide an update on the current view of the antitumor activity of targeting CD73 by mAb or small molecule selective inhibitors in preclinical and clinical settings.
Insights
CD73 blockade, combined with other therapies, shows promise in fighting cancer by boosting immune response. This strategy is effective in preclinical models and early clinical trials for advanced solid tumors.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- CD73 is an immune checkpoint enzyme linked to adenosine metabolism.
- It promotes tumor growth by hindering anti-tumor immunity and encouraging angiogenesis.
- CD73 plays a role in tumor progression and immune evasion.
Purpose of the Study:
- To review the role of CD73 in tumor immunity and tumorigenesis.
- To summarize the antitumor effects of CD73 inhibition in preclinical and clinical settings.
- To discuss the combination of anti-CD73 therapies with other cancer treatments.
Main Methods:
- Review of preclinical mouse models of cancer.
- Analysis of emerging clinical data for advanced solid tumors.
- Discussion of monoclonal antibodies (mAbs) and small molecule inhibitors targeting CD73.
Main Results:
- CD73 inhibition, especially combined with immune checkpoint blockade, enhances anti-tumor effects.
- Preclinical studies demonstrate improved outcomes with CD73 targeting.
- Early clinical trials show promising activity in patients with advanced solid tumors.
Conclusions:
- Targeting CD73 is a promising strategy for cancer therapy.
- Combination therapies involving CD73 inhibition warrant further investigation.
- CD73 blockade offers a potential approach to overcome tumor-induced immunosuppression.
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Tumor Immunotherapy
Emerging Adulthood
Introduction Cardiac Emergencies
Applications of GIS: Disaster Management and Emergency Response
Cancer

